Skip to content

The 90% effective dose of Methoxamine intermittent intravenous boluses for preventing spinal-induced hypotension during cesarean delivery

The 90% effective dose of Methoxamine intermittent intravenous boluses for preventing spinal-induced hypotension during cesarean delivery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043096
Enrollment
Unknown
Registered
2021-02-05
Start date
2021-02-06
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal-induced hypotension

Interventions

methoxamine group:The corresponding dose of methoxide (1mg, 1.5mg, 2mg, 2.5mg, 3mg, 3.5mg IV) shall be given according to the drug reaction of the previous case

Sponsors

West China Second University Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Parturients, American Society of Anesthesiologists physical status (ASA <= II), singleton pregnancy, scheduled for elective cesarean delivery, undertaken combined spinal-epidural anesthesia.

Exclusion criteria

Exclusion criteria: Body mass index > 30kg/m2, height 170 cm, anemia (hemoglobin < 9 g/dl ), known cardiovascular or cerebrovascular disease, pre-existing or pregnancy-induced hypertension, diabetes mellitus, fetal abnormality, monoamine oxidase inhibitors undertaken or contraindication to spinal anesthesia.

Design outcomes

Primary

MeasureTime frame
the success of intermittent boluses of the assigned dose of methoxide to prevent hypotension;

Secondary

MeasureTime frame
the incidence of bradycardia;the incidence of reactive hypertension;umbilical blood pH;

Countries

China

Contacts

Public ContactXuemei Lin

Department of Anesthesiology, West China Second University Hospital,Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University

xuemeilin__scu@163.com+86 18180609220

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026